论文部分内容阅读
目的:观察N-乙酰转移酶NAT10蛋白在软组织肉瘤中的表达及与类型、分级的关系。方法:通过原核表达NAT10蛋白免疫制备特异性多克隆抗体,并经免疫印迹鉴定;以组织芯片-免疫组化检测166例软组织肉瘤和28例良性肿瘤及瘤样病变中NAT10蛋白的表达。结果:制备多克隆抗体经Western印迹鉴定与NAT10具有特异结合性。免疫组化显示166例软组织肉瘤中NAT10蛋白阳性95例,阳性率为57%(95/166),28例良性肿瘤及瘤样病变中4例阳性14%(4/28),两者间有显著性差异(P<0.05)。NAT10表达的主要分布为:滑膜肉瘤76%(13/17)、恶性纤维组织细胞瘤75%(15/20)、原始神经外胚叶瘤(PNET)70%(16/23)、横纹肌肉瘤70%(7/10)、恶性外周神经鞘膜瘤50%(11/22)、隆突性皮肤纤维肉瘤50%(7/14)、平滑肌肉瘤43%(6/14)、脂肪肉瘤42%(8/19)、黏液性纤维肉瘤38%(6/16)。统计比较显示:滑膜肉瘤与黏液性纤维肉瘤和脂肪肉瘤,以及恶性纤维组织细胞瘤与黏液性纤维肉瘤之间NAT10表达具有显著性差异(P<0.05);而其它各组间无明显差异(P>0.05)。同时,NAT10蛋白强阳性表达(≥++)多存在于滑膜肉瘤(53%,9/17)、横纹肌肉瘤(40%,4/10)及恶性纤维组织细胞瘤(40%,8/20)。在FNCLCC分级中,19例I级肉瘤中NAT10阳性表达率为42%(8/19),44例II级肉瘤为43%(19/44),70例III级肉瘤为73%(51/70)。III级NAT10阳性率显著高于II级组和I级组(均为P<0.05)。结论:研究表明N-乙酰转移酶NAT10表达于多种人软组织肉瘤,尤其在高度恶性肉瘤,因此有可能为软组织肉瘤的分级及预后因子。
Objective: To investigate the expression of N-acetyltransferase NAT10 in soft tissue sarcoma and its relationship with type and grade. Methods: The specific polyclonal antibody was prepared by immunoprecipitation of NAT10 protein and identified by Western blot. The expression of NAT10 protein in 166 soft tissue sarcomas and 28 benign tumors and tumor-like lesions was detected by tissue chip immunohistochemistry. Results: The prepared polyclonal antibodies were identified by Western blot with specific binding to NAT10. Immunohistochemistry showed that NATO1 protein was positive in 166 of 166 soft tissue sarcomas, with a positive rate of 57% (95/166). Among 28 benign tumors and 4 cases of tumor-like lesions, 4 were positive (14/28) Significant difference (P <0.05). The main distribution of NAT10 expression was synovial sarcoma 76% (13/17), malignant fibrous histiocytoma 75% (15/20), primitive neuroectodermal tumor (PNET) 70% (16/23), rhabdomyosarcoma 70% (7/10), 50% (11/22) of malignant peripheral nerve sheath tumor, 50% (7/14) of lenticular fibrosarcoma, 43% (6/14) of leiomyosarcoma, 42% (8/19), myxoma fibrosarcoma 38% (6/16). Statistical comparison showed that the expression of NAT10 was significantly different between synovial sarcoma and mucinous fibrosarcoma and liposarcoma, as well as between malignant fibrous histiocytoma and mucinous fibrosarcoma (P <0.05), while there was no significant difference between the other groups P> 0.05). Meanwhile, the strong positive expression of NAT10 protein (≥ ++) was found in synovial sarcoma (53%, 9/17), rhabdomyosarcoma (40%, 4/10) and malignant fibrous histiocytoma (40%, 8/20 ). In the FNCLCC grading, the positive rate of NAT10 was 42% (8/19) in 19 cases of grade I sarcomas, 43% (44/44) in 44 cases of class II sarcomas, 73% (51/70) in 70 cases of class III sarcomas ). The positive rate of grade III NAT10 was significantly higher than that of grade II and group I (all P <0.05). CONCLUSIONS: Studies have shown that N-acetyltransferase NAT10 is expressed in a variety of human soft tissue sarcomas, especially in highly malignant sarcomas, and is therefore likely to be a grade and prognostic factor for soft tissue sarcomas.